PATH
Seattle, Washington, United States
Purpose
to compare the immunogenicity of two developing country vaccine manufacturers HPV9 products to currently licensed HPV9 products.
Division
Global Health
Date
November 2022
Region Served
GLOBAL
Committed amount
$9,224,037
Grant topic
Vaccine Development
Duration (months)
67
Grantee location
Seattle, Washington, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.